Rito® 60 Tablet: Each film-coated tablet contains Etoricoxib INN 60 mg.
Rito® 90 Tablet: Each film-coated tablet contains Etoricoxib INN 90 mg.
Rito® 120 Tablet: Each film-coated tablet contains Etoricoxib INN 120 mg.
Etoricoxib is a non-steroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic and antipyretic activities. It is a potent, orally active, highly selective cyclooxygenase-2 (COX-2) inhibitor within and above the clinical dose range.
Mode of action:
Etoricoxib exhibits anti-inflammatory, analgesic and antipyretic activities by inhibiting cyclooxygenase-2 (COX-2) enzyme and decreases these clinical signs and symptoms with decreased GI toxicity and without effects on platelet function.
Pharmacokinetics:
Orally administered etoricoxib is well absorbed. The absolute bioavailability is approximately 100%. Dosing with food has no effect on the extent of absorption of etoricoxib after administration of a 120 mg dose. The rate of absorption is affected, resulting in a 36% decrease in Cmax and an increase in Tmax by 2 hours. Etoricoxib is approximately 92% bound to human plasma protein over the range of concentrations of 0.05 to 5 µg/ml. Elimination of etoricoxib occurs almost exclusively through metabolism followed by renal excretion.
Rito® (Etoricoxib) is indicated for relief of pain and inflammation in.
Adult and adolescent over 16 years:
Oral anticoagulants, diuretics and ACE inhibitors, Acetylsalicylic acid, Cyclosporin and Tacrolimus, Lithium, Methotrexate, oral contraceptives, Prednisone/Prednisolone, Digoxin, drugs metabolized by sulfotransferases (Ethynyl Estradiol), drugs metabolized by CYP isoenzymes, Ketoconazole, Rifampicin, and Antacids have interaction with Etoricoxib.
As with other drugs known to inhibit prostaglandin synthesis, use of it should be avoided in late pregnancy because it may cause premature closure of the ductus arteriosus. It should be used during the first two trimesters of pregnancy only if the potential benefit justifies the potential risk to the foetus. It is not known whether this drug is excreted in human milk.
A patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver function test has occurred, should be evaluated for persistently abnormal liver function tests. If persistently abnormal liver function tests (three times the upper limit of normal) are detected, it should be discontinued. It should be used with caution in patients who have previously experienced acute asthmatic attacks, urticaria, or rhinitis, which were precipitated by salicylates or non-selective cyclooxygenase inhibitors. It may mask fever, which is a sign of infection.
Store in a cool and dry place, protected from light.